DRUG-RESISTANCE MUTATIONS
Emergence of HIV 1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana
9
Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran
9
Sensitivity and Specificity of the ViroSeq Human Immunodeficiency Virus Type 1 (HIV 1) Genotyping System for Detection of HIV 1 Drug Resistance Mutations by Use of an ABI PRISM 3100 Genetic Analyzer
5
<p>Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam</p>
6
Stochastic Interplay between Mutation and Recombination during the Acquisition of Drug Resistance Mutations in Human Immunodeficiency Virus Type 1
7
Detection of Cytomegalovirus Drug Resistance Mutations by Next Generation Sequencing
11
Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil
7
Pre treatment minority HIV 1 drug resistance mutations and long term virological outcomes: is prediction possible?
9
Using Aspergillus nidulans To Identify Antifungal Drug Resistance Mutations
7
Prevalence of Human Immunodeficiency Virus Drug Resistance Mutations and Subtypes in Drug Naive, Infected Individuals in the Army Health Service of Rio de Janeiro, Brazil
5
KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking
10
Effect of Transmission Reduction by Insecticide-Treated Bednets (ITNs) on Antimalarial Drug Resistance in Western Kenya
10
Accuracy of the TRUGENE HIV 1 Genotyping Kit
8
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
16
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
14
Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014
10
Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011
8
Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy
7
Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults
11
Validation of an Oligonucleotide Ligation Assay for Quantification of Human Immunodeficiency Virus Type 1 Drug Resistant Mutants by Use of Massively Parallel Sequencing
8